Get started
Author

Ann M. Mohrbacher

Observed name: Anne Mohrbacher
OpenAlex ID: A5080835541
Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study
2021 · Gareth P. Gregory, Shaji Kumar, et al. · Blood Advances · 40
Supplemental Table 3 from Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial
2023 · Ann M. Mohrbacher, Allen S. Yang, et al.
Supplemental Table 1 from Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial
2023 · Ann M. Mohrbacher, Allen S. Yang, et al.
Supplemental Table 1 from Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial
2023 · Ann M. Mohrbacher, Allen S. Yang, et al.
Supplemental Table 3 from Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial
2023 · Ann M. Mohrbacher, Allen S. Yang, et al.
Supplemental Table 2 from Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial
2023 · Ann M. Mohrbacher, Allen S. Yang, et al.
Supplemental Table 4 from Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial
2023 · Ann M. Mohrbacher, Allen S. Yang, et al.
Data from Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial
2023 · Ann M. Mohrbacher, Allen S. Yang, et al.
Data from Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial
2023 · Ann M. Mohrbacher, Allen S. Yang, et al.
Supplemental Table 4 from Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial
2023 · Ann M. Mohrbacher, Allen S. Yang, et al.
Supplemental Table 2 from Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial
2023 · Ann M. Mohrbacher, Allen S. Yang, et al.
Works count: 11
Citation count: 40
H-index: 1
I10-index: 1
Year
Topic
Type